108.26
price up icon1.17%   1.25
after-market Handel nachbörslich: 108.26
loading
Schlusskurs vom Vortag:
$107.01
Offen:
$108.16
24-Stunden-Volumen:
826.42K
Relative Volume:
0.64
Marktkapitalisierung:
$6.67B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
15.25
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
+0.41%
1M Leistung:
-7.00%
6M Leistung:
-10.96%
1J Leistung:
+3.85%
1-Tages-Spanne:
Value
$107.36
$109.58
1-Wochen-Bereich:
Value
$106.01
$110.48
52-Wochen-Spanne:
Value
$95.49
$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
Firmenname
Jazz Pharmaceuticals Plc
Name
Telefon
353-1-634-7800
Name
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
Mitarbeiter
2,800
Name
Twitter
@jazzpharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
JAZZ's Discussions on Twitter

Vergleichen Sie JAZZ mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
108.26 6.64B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.68 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.09 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 40.37M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.39 64.44B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
77.49 6.19B 0 -153.72M -103.81M -2.00

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-07 Hochstufung UBS Neutral → Buy
2025-02-26 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-02-13 Hochstufung Wells Fargo Equal Weight → Overweight
2024-12-12 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-06-05 Eingeleitet Goldman Buy
2024-01-03 Eingeleitet Robert W. Baird Outperform
2023-11-27 Herabstufung UBS Buy → Neutral
2023-09-29 Eingeleitet Raymond James Mkt Perform
2023-06-12 Fortgesetzt Wells Fargo Equal Weight
2022-12-09 Hochstufung Goldman Neutral → Buy
2022-06-14 Eingeleitet UBS Buy
2022-04-06 Herabstufung Goldman Buy → Neutral
2021-11-19 Fortgesetzt Goldman Buy
2021-10-07 Fortgesetzt Jefferies Buy
2021-10-05 Eingeleitet Citigroup Buy
2021-09-23 Eingeleitet Needham Buy
2021-05-19 Fortgesetzt JP Morgan Overweight
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2021-02-05 Bestätigt H.C. Wainwright Buy
2021-02-03 Hochstufung Piper Sandler Neutral → Overweight
2021-01-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-12-16 Eingeleitet UBS Buy
2020-11-03 Bestätigt H.C. Wainwright Buy
2020-10-09 Bestätigt H.C. Wainwright Buy
2020-09-14 Herabstufung Goldman Neutral → Sell
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-08-06 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-07-28 Hochstufung Wolfe Research Peer Perform → Outperform
2020-07-23 Hochstufung H.C. Wainwright Neutral → Buy
2020-04-06 Eingeleitet Jefferies Buy
2020-03-12 Hochstufung Bernstein Mkt Perform → Outperform
2020-01-08 Eingeleitet Goldman Neutral
2019-08-21 Herabstufung Piper Jaffray Overweight → Neutral
2019-06-11 Eingeleitet Barclays Overweight
2019-03-20 Eingeleitet SunTrust Buy
2018-12-14 Eingeleitet Wolfe Research Peer Perform
2018-11-08 Bestätigt B. Riley FBR Buy
2018-08-08 Bestätigt Stifel Buy
2018-07-11 Herabstufung Morgan Stanley Overweight → Equal-Weight
2018-03-23 Bestätigt H.C. Wainwright Neutral
2018-03-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
Alle ansehen

Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten

pulisher
07:47 AM

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus

07:47 AM
pulisher
07:30 AM

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire

07:30 AM
pulisher
May 24, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Deutsche Bank AG - Defense World

May 24, 2025
pulisher
May 23, 2025

Cetera Investment Advisers Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World

May 23, 2025
pulisher
May 23, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

May 23, 2025
pulisher
May 23, 2025

Idiopathic Hypersomnia Treatment Market: Drug Pipeline, - openPR.com

May 23, 2025
pulisher
May 22, 2025

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - Citizen Tribune

May 22, 2025
pulisher
May 21, 2025

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences | JAZZ Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Jazz Pharmaceuticals Leadership to Present Strategic Updates at Two Major Healthcare Conferences in June - Stock Titan

May 21, 2025
pulisher
May 21, 2025

Psychedelic Drugs Market Opportunities in the United States - openPR.com

May 21, 2025
pulisher
May 21, 2025

Jazz Pharmaceuticals: One Step Forward, One Back (NASDAQ:JAZZ) - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

Transcript : Jazz Pharmaceuticals plc Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com

May 21, 2025
pulisher
May 20, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Cut by Cubist Systematic Strategies LLC - Defense World

May 20, 2025
pulisher
May 19, 2025

JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

Mercer Global Advisors Inc. ADV Has $202,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World

May 18, 2025
pulisher
May 16, 2025

Jazz outlines $4.15B-$4.4B revenue target for 2025 amid growth in neuroscience portfolio and new oncology approvals - MSN

May 16, 2025
pulisher
May 16, 2025

Weekly Investment Analysts’ Ratings Updates for Jazz Pharmaceuticals (JAZZ) - Defense World

May 16, 2025
pulisher
May 15, 2025

July 18th Options Now Available For Jazz Pharmaceuticals - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Jazz Pharma stock falls after lowered full year guidance - MSN

May 15, 2025
pulisher
May 15, 2025

Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings May Just Be The Starting Point - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to “Hold” at StockNews.com - Defense World

May 15, 2025
pulisher
May 14, 2025

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance - ADVFN

May 14, 2025
pulisher
May 14, 2025

Jazz Pharmaceuticals at Bank of America 2025: Strategic Growth Amid Challenges - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance

May 13, 2025
pulisher
May 10, 2025

Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

May 10, 2025
pulisher
May 09, 2025

Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma - MSN

May 09, 2025
pulisher
May 09, 2025

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Hikma $50M Deal to Settle Xyrem Antitrust Claims - USA Herald

May 09, 2025
pulisher
May 09, 2025

Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st

May 09, 2025
pulisher
May 09, 2025

Jazz Pharmaceuticals plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Royal Bank of Canada Has Lowered Expectations for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World

May 09, 2025
pulisher
May 09, 2025

StockNews.com Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy - Defense World

May 09, 2025
pulisher
May 09, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL - Law360

May 08, 2025
pulisher
May 08, 2025

Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - Reuters

May 08, 2025
pulisher
May 08, 2025

JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - MSN

May 08, 2025
pulisher
May 08, 2025

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com

May 08, 2025
pulisher
May 08, 2025

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM) - The Globe and Mail

May 08, 2025
pulisher
May 08, 2025

Jazz Earnings: Strong Demand for Epidiolex and Xywav Drive Growth; Shares Very Undervalued - Morningstar

May 08, 2025
pulisher
May 08, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Gap Down After Earnings Miss - Defense World

May 08, 2025
pulisher
May 08, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

May 08, 2025
pulisher
May 08, 2025

Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Jazz Pharmaceuticals (JAZZ) Rating Maintained Despite Price Target Cut | JAZZ Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

RBC Capital Maintains Outperform Rating on Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Jazz Pharmaceuticals (JAZZ): Morgan Stanley Adjusts Price Target - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Jazz Pharmaceuticals (JAZZ) Target Price Lowered by Piper Sandler | JAZZ Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

RBC Capital Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Jazz Pharmaceuticals (JAZZ) Price Target Reduced by Morgan Stanl - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Jazz Pharmaceuticals (JAZZ) Maintains Strong Momentum with 'Buy' Rating | JAZZ Stock News - GuruFocus

May 07, 2025

Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
Kapitalisierung:     |  Volumen (24h):